Multiple Sclerosis (MS) Market Analysis, Market size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

Tuesday, December 4, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

LAS VEGAS, December 4, 2018 /PRNewswire/ --

The market of Multiple Sclerosis (MS) in 7MM was found to be USD 21,248 million in 2016, and is expected to increase in 2027.


Multiple Sclerosis (MS) is an unpredictable autoimmune disease that affects the central nervous system. In Multiple Sclerosis (MS), body's own immune system produces cells and proteins (antibodies) that attack the fatty substance,

myelin, which is responsible for protecting the body's nerve fibers. There are four major categories in Multiple Sclerosis (MS):- Relapsing-Remitting Multiple Sclerosis, Secondary-Progressive Multiple Sclerosis, Primary-Progressive Multiple Sclerosis, and Progressive-Relapsing Multiple Sclerosis.

     (Logo: )

According to DelveInsight, the total prevalent population of Multiple Sclerosis (MS) in 7 major markets is estimated to be approximately 1,980,782 in 2016, which is then expected to increase in the forecasted period of 2018-2027. It is also estimated that prevalence of Multiple Sclerosis (MS) in United States with 1,301,558 cases in 2016 will increase in 2027. The market of Multiple Sclerosis (MS) in 7MM was found to be USD 21,248 million in 2016, and is expected to increase in 2027. Additionally, the United States accounts for the largest market size of Multiple Sclerosis (MS), in comparison to other 7 MM countries i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

Presently, there are some therapies approved by the FDA for the treatment of Multiple Sclerosis (MS), which include Betaferon, Rebif, Copaxone, Avonex, Tysabri, Fampyra/Ampyra, Gilenya, Aubagio, Tecfidera, Plegridy, Lemtrada, Zinbryta, Ocrevus, and Mavenclad, among others. Apart from all these approved products, there are few more promising candidates in pivotal stages of clinical development, to increase the market size of Multiple Sclerosis (MS) during the forecast period (2018-2027). These emerging drugs mainly include Siponimod (BAF312; Novartis), Ponesimod (ACT-128800; Johnson and Johnson), Ozanimod (RPC1063; Celgene), Ofatumumab (Novartis), Ublituximab (TG Therapeutics), ALKS 8700 (Alkermes Plc), Gocovri (Adamas Pharmaceuticals), Evobrutinib (Merck KgaA), and Mavenclad (Merck KgaA).

This report provides current treatment practices, emerging drugs, market share of individual therapies, current and forecasted market size of Multiple Sclerosis (MS) from 2016 to 2027, segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Click here to get a sample report:,-Epidemiology-and-Market-Forecast---2028

Key Benefits • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Multiple Sclerosis (MS) market • Organize sales and marketing efforts by identifying the best opportunities for Multiple Sclerosis (MS) market • To understand the future market competition in the Multiple Sclerosis (MS) market.

Companies covered 

  1. Bayer Healthcare
  2. Merck KGA
  3. Teva Pharmaceutical
  4. Biogen
  5. Novartis

And many others

Drugs covered 

  1. Betaferon
  2. Rebif
  3. Copaxone
  4. Avonex
  5. Tysabri

And many others

Key topics covered 

1. Key Insights 2. Multiple Sclerosis (MS) Market Overview at a Glance 3. Multiple Sclerosis (MS): Disease Background and Overview 4. Epidemiology and Patient Population 5. Country Wise-Epidemiology of Multiple Sclerosis (MS) 5.1. United States 6. EU5 Countries 7. Japan 8. Treatment 9. Unmet Needs 10. Marketed Drugs 10.1. Betaferon: Bayer Healthcare 10.2. Rebif: Merck KGA 10.3. Copaxone: Teva Pharmaceutical 10.4. Avonex: Biogen Idec. Limited 10.5. Tysabri: Biogen Idec. Limited 10.6. Fampyra/Ampyra: Acorda Therapeutics/ Biogen Idec Ltd. 10.7. Gilenya: Novartis 10.8. Aubagio: Genzyme 10.9. Tecfidera: Biogen Idec Ltd. 10.10. Plegridy: Biogen Idec Ltd. 10.11. Lemtrada: Genzyme 10.12. Zinbryta: Biogen Idec 10.13. Ocrevus: Genentech 10.14. Mavenclad: Merck 11. Emerging Drugs 11.1. Key Cross Competition 11.2. Phase III Drugs 11.2.1. ALKS 8700: Biogen 11.2.2. Ublituximab: TG Therapeutics 11.2.3. Ozanimod: Celgene Corporation 11.2.4. OMB157: Novartis 11.2.5. MD1003: MedDay Pharma 11.2.6. Masitinib: AB Science 11.2.7. Siponimod: Novartis 11.2.8. Ponesimod: Johnson & Johnson 11.2.9. Evobrutinib: Merck 11.2.10. ADS-5102: Adamas Pharmaceuticals 12. Multiple Sclerosis (MS): 7 Major Market Analysis 13. Global Market Size by Therapies 14. The United States Market Outlook 15. EU-5 Countries: Market Outlook 16. Japan-MS Market Size 17. Cost Analysis of Multiple Sclerosis (MS) 18. Generic Competition in MS Market 19. Market Drivers 20. Market Barriers 21. Appendix 22. DelveInsight Capabilities 23. Disclaimer 24. About DelveInsight

Click here to get a WebEx demo:

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us: Shruti Thakur +919650213330

SOURCE DelveInsight Business Research, LLP

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store